Feoza^TM

Indication:
Fezolinetant is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.

Dosage & Administration:
A single 45 mg Fezolinetant tablet orally once daily with or without food.
While using Fezolinetant, patient should perform follow-up hepatic laboratory tests monthly for the first 3 months, at 6 months, and 9 months after initiation of therapy or when signs or symptoms suggest liver injury.

Preparation:
Each box contains 2 Alu-PVDC blister strips of 10 tablets.